Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cllc.2021.01.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety of brigatinib following alectinib-induced-pneumonitis: Case report.
Respir Med Case Rep
December 2024
Department of Medicine V, LMU University Hospital, LMU Munich, Germany.
Anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK TKIs) show robust efficacy and has revolutionized the treatment of NSCLC patients harboring an ALK-rearrangement. Side effects, sometimes even serious such as pneumonitis, can occur with ALK TKIs. We report a case of a patient with ALK positive advanced NSCLC who developed pneumonitis during treatment with first-line alectinib.
View Article and Find Full Text PDFThe evolving landscape of adjuvant therapy in T1-T2N0 resected non-small cell lung cancer: a narrative review.
J Thorac Dis
December 2024
Department of Surgery, Yale University School of Medicine, Yale University, New Haven, CT, USA.
Background And Objective: Lung cancer recurrence after complete surgical resection of early-stage T1-T2N0 non-small cell lung cancer (NSCLC) remains a problem due to unrecognized micrometastatic disease. The objective of this review is to present and summarize data from major randomized trials in which have studied the survival benefit of adjuvant therapy for early-stage NSCLC.
Methods: Information used to write this paper was collected from PubMed and the National Clinical Trial registry from the National Library of Medicine.
Characteristics of the immune microenvironment and their clinical significance in lung adenocarcinoma patients with different ALK fusion variants.
Transl Lung Cancer Res
December 2024
Department of Pathology, Molecular Pathology Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Background: The tumor immune microenvironment of anaplastic lymphoma kinase (ALK)-rearranged lung adenocarcinoma (LUAD) stratified by ALK fusion variants is poorly pictured. Hence, in this study, we aim to explore the immune heterogeneity of ALK LUAD across different ALK fusion variants and further investigate their significance on clinical prognosis.
Methods: A retrospective analysis was conducted on ALK LUAD patients (N=68).
ALK-rearranged primary mixed mucinous and non-mucinous lung adenocarcinoma: A case report.
Rev Esp Patol
January 2025
Department of Pathology, Instituto Nacional de Cancerología, Bogotá, Colombia; Research Institute, Fundación Universitaria de Ciencias de la Salud (FUCS), Bogotá, Colombia. Electronic address:
Lung cancer exhibits a diverse array of morphological manifestations and molecular changes, significantly influencing patient diagnosis, prognosis, and treatment strategies. We present the case of a 47-year-old man with a history of smoking, who presented to the emergency room with a 12-month history of haemoptysis. A chest computed tomography (CT) scan revealed a mass in the right upper lobe of the lung and bilateral lung nodules.
View Article and Find Full Text PDFRenal cell carcinoma with ALK-TPM3 gene fusion and ALK amplification: A case report and literature review.
Pathol Res Pract
January 2025
Department of Pathology, Air Force Medical Center, PLA, Beijing, PR China. Electronic address:
Background: Anaplastic lymphoma kinase (ALK)-rearranged renal cell carcinoma (ALK-RCC) is a rare molecularly defined tumor entity included in the fifth edition of the World Health Organization Classification of Tumors. It is characterized by rearrangement of the ALK gene with various fusion partner genes, which most commonly results in oncogenic fusion proteins leading to ALK activation.
Case Presentation: A 30-year-old Chinese man underwent partial nephrectomy for a left renal tumor measuring 5 cm in diameter.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!